691 related articles for article (PubMed ID: 24444383)
1. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
2. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
[TBL] [Abstract][Full Text] [Related]
3. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.
Johnson N; Bentley J; Wang LZ; Newell DR; Robson CN; Shapiro GI; Curtin NJ
Br J Cancer; 2010 Jan; 102(2):342-50. PubMed ID: 20010939
[TBL] [Abstract][Full Text] [Related]
4. Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition.
Kumarasamy V; Vail P; Nambiar R; Witkiewicz AK; Knudsen ES
Cancer Res; 2021 Mar; 81(5):1347-1360. PubMed ID: 33323381
[TBL] [Abstract][Full Text] [Related]
5. Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27.
García-Gutiérrez L; Bretones G; Molina E; Arechaga I; Symonds C; Acosta JC; Blanco R; Fernández A; Alonso L; Sicinski P; Barbacid M; Santamaría D; León J
Sci Rep; 2019 Dec; 9(1):18693. PubMed ID: 31822694
[TBL] [Abstract][Full Text] [Related]
6. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
Cho SJ; Lee SS; Kim YJ; Park BD; Choi JS; Liu L; Ham YM; Moon Kim B; Lee SK
Cancer Lett; 2010 Jan; 287(2):196-206. PubMed ID: 19616371
[TBL] [Abstract][Full Text] [Related]
7. Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2.
Pack LR; Daigh LH; Chung M; Meyer T
Nat Commun; 2021 Jun; 12(1):3356. PubMed ID: 34099663
[TBL] [Abstract][Full Text] [Related]
8. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.
Gogolin S; Ehemann V; Becker G; Brueckner LM; Dreidax D; Bannert S; Nolte I; Savelyeva L; Bell E; Westermann F
Cell Cycle; 2013 Apr; 12(7):1091-104. PubMed ID: 23462184
[TBL] [Abstract][Full Text] [Related]
9. The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G₁ cell-cycle arrest and not a direct effect on BIK protein stability.
Sale MJ; Cook SJ
Biochem J; 2014 May; 459(3):513-24. PubMed ID: 24527759
[TBL] [Abstract][Full Text] [Related]
10. Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.
AbuHammad S; Cullinane C; Martin C; Bacolas Z; Ward T; Chen H; Slater A; Ardley K; Kirby L; Chan KT; Brajanovski N; Smith LK; Rao AD; Lelliott EJ; Kleinschmidt M; Vergara IA; Papenfuss AT; Lau P; Ghosh P; Haupt S; Haupt Y; Sanij E; Poortinga G; Pearson RB; Falk H; Curtis DJ; Stupple P; Devlin M; Street I; Davies MA; McArthur GA; Sheppard KE
Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17990-18000. PubMed ID: 31439820
[TBL] [Abstract][Full Text] [Related]
11. Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.
Guarducci C; Nardone A; Russo D; Nagy Z; Heraud C; Grinshpun A; Zhang Q; Freelander A; Leventhal MJ; Feit A; Cohen Feit G; Feiglin A; Liu W; Hermida-Prado F; Kesten N; Ma W; De Angelis C; Morlando A; O'Donnell M; Naumenko S; Huang S; Nguyen QD; Huang Y; Malorni L; Bergholz JS; Zhao JJ; Fraenkel E; Lim E; Schiff R; Shapiro GI; Jeselsohn R
Clin Cancer Res; 2024 May; 30(9):1889-1905. PubMed ID: 38381406
[TBL] [Abstract][Full Text] [Related]
12. 4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells.
Satriyo PB; Su CM; Ong JR; Huang WC; Fong IH; Lin CC; Aryandono T; Haryana SM; Deng L; Huang CC; Tzeng YM; Chao TY; Liu HW; Yeh CT
Toxicol Appl Pharmacol; 2021 Jul; 422():115493. PubMed ID: 33727089
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor binding protein-3 induces G1 cell cycle arrest with inhibition of cyclin-dependent kinase 2 and 4 in MCF-7 human breast cancer cells.
Kim HS; Lee WJ; Lee SW; Chae HW; Kim DH; Oh Y
Horm Metab Res; 2010 Mar; 42(3):165-72. PubMed ID: 19960406
[TBL] [Abstract][Full Text] [Related]
14. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
[TBL] [Abstract][Full Text] [Related]
15. Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells.
Patel P; Tsiperson V; Gottesman SRS; Somma J; Blain SW
Mol Cancer Res; 2018 Mar; 16(3):361-377. PubMed ID: 29330290
[TBL] [Abstract][Full Text] [Related]
16. Selective CDK4/6 inhibition of novel 1,2,3-triazole tethered acridinedione derivatives induces G1/S cell cycle transition arrest via Rb phosphorylation blockade in breast cancer models.
Praveenkumar E; Gurrapu N; Kolluri PK; Shivaraj ; Subhashini NJP; Dokala A
Bioorg Chem; 2021 Nov; 116():105377. PubMed ID: 34670329
[TBL] [Abstract][Full Text] [Related]
17. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.
Spring L; Bardia A; Modi S
Discov Med; 2016 Jan; 21(113):65-74. PubMed ID: 26896604
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC.
Goga A; Yang D; Tward AD; Morgan DO; Bishop JM
Nat Med; 2007 Jul; 13(7):820-7. PubMed ID: 17589519
[TBL] [Abstract][Full Text] [Related]
19. Mice thrive without Cdk4 and Cdk2.
Barrière C; Santamaría D; Cerqueira A; Galán J; Martín A; Ortega S; Malumbres M; Dubus P; Barbacid M
Mol Oncol; 2007 Jun; 1(1):72-83. PubMed ID: 19383288
[TBL] [Abstract][Full Text] [Related]
20. The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells.
Fu W; Ma L; Chu B; Wang X; Bui MM; Gemmer J; Altiok S; Pledger WJ
Mol Cancer Ther; 2011 Jun; 10(6):1018-27. PubMed ID: 21490307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]